Monte Rosa Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.08B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $9.00M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $4.20M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 17, 2026 | Before market open | $2.80M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $12.80M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $23.20M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $84.90M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 10, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $9.20M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
Press releases
Announcements Monte Rosa Therapeutics filed with the SEC
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Degrading Proteins, Making Medicines MRT-8102 GFORCE-1 Clinical Study Results October 1, 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Degrading Proteins, Making Medicines MRT-8102 Phase 1 Clinical Data Update January 7, 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Degrading Proteins, Making Medicines MRT-2359 Phase 1/2 Clinical Data Update December 16, 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | May 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | March 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | January 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | December 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Regulation FD disclosure · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Leadership Team Promotions
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | May 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D.,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | March 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2024
Regulation FD disclosure · EX-99.2 to Form 8-K
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | October 2023
Material agreement · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K